Drug Trial Radar · NCT07072611
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 14, 2025
Primary completion
Dec 27, 2025
Study completion May 5, 2026
Sponsor
- Lead sponsor
- Noxopharm LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2. Part 1, is a single ascending dose (SAD) design, while Part 2 is a multiple ascending dose (MAD) design.
Conditions
- Cutaneous Lupus Erythematosus
Interventions
SOF-SKN 0.25%Drug
cream for topical application
SOF-SKN 0.5%Drug
cream for topical application
SOF-SKN 1%Drug
cream for topical application
SOF-SKN 2%Drug
cream for topical application
PlaceboDrug
cream for topical application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Target Toxicities after a single treatmentTime frame: 4 days -3 days after last application of topical treatment
- Percentage of Target Toxicities after two-week treatmentTime frame: 17 days - 3 days after last dose of treatment
- Percentage of Adverse events (AEs) after a single treatmentTime frame: 4 days -3 days after last application of topical treatment
- Percentage of Adverse events (AEs) after two-week treatmentTime frame: 17 days - 3 days after last dose of treatment
- Percentage of Serious Adverse events (SAEs) after a single treatmentTime frame: 4 days -3 days after last application of topical treatment
- Percentage of serious Adverse events (SAEs) after two-week treatmentTime frame: 17 days - 3 days after last dose of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Doherty Clinical Trials
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.